Michael Lein

7.7k total citations · 1 hit paper
171 papers, 5.9k citations indexed

About

Michael Lein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michael Lein has authored 171 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 42 papers in Molecular Biology. Recurrent topics in Michael Lein's work include Prostate Cancer Treatment and Research (87 papers), Prostate Cancer Diagnosis and Treatment (71 papers) and Protease and Inhibitor Mechanisms (22 papers). Michael Lein is often cited by papers focused on Prostate Cancer Treatment and Research (87 papers), Prostate Cancer Diagnosis and Treatment (71 papers) and Protease and Inhibitor Mechanisms (22 papers). Michael Lein collaborates with scholars based in Germany, United States and Switzerland. Michael Lein's co-authors include Klaus Jung, Carsten Stephan, Stefan A. Loening, Dietmar Schnorr, Glen Kristiansen, Kurt Miller, Monika Jung, Pranav Sinha, Florian Jentzmik and Mark Schrader and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer and Oncogene.

In The Last Decade

Michael Lein

167 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma

2009 524 citations Monika Jung, Carsten Stephan et al. International Journal of Cancer profile →

Peers

Countries citing papers authored by Michael Lein

Since Specialization

Citations

This map shows the geographic impact of Michael Lein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lein more than expected).

Fields of papers citing papers by Michael Lein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lein. The network helps show where Michael Lein may publish in the future.

Co-authorship network of co-authors of Michael Lein

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Lein. A scholar is included among the top collaborators of Michael Lein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Lein. Michael Lein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety with the senhance™ robotic system in 3,239 patients across various surgical disciplines 2025 ·Langenbeck s Archives of Surgery ·Ludger Staib, Frank Willeke, (unknown), (unknown), Olaf Hansen, Narimantas Evaldas Samalavičius, (unknown), Burghard Abendstein, Tomislav Kuliš, Christian Jackisch, Michael Lein, Johannes Schmidt, (unknown), Michael Möller	1
2	Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy 2022 ·Cancers ·Carsten Stephan, Bernhard Ralla, Florian Bonn, (unknown), Michael Lein, Klaus Jung	1
3	サブサイクル制御強力二色場におけるHeH+の解離とイオン化【JST・京大機械翻訳】 2020 ·Journal of Physics B Atomic Molecular and Optical Physics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Michael Lein	1
4	Comparison of surgical technique (Open vs. Laparoscopic) on pathological and long term functional outcomes following radical prostatectomy 2014 ·BMC Urology ·Ahmed Magheli, Jonas Busch, (unknown), Mark Schrader, Serdar Değer, Kurt Miller, Michael Lein	18
5	Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohort 2010 ·Modern Pathology ·Raquel Esgueva, Sven Perner, Christopher J. Lafargue, Veit Scheble, Carsten Stephan, Michael Lein, Florian Fritzsche, Manfred Dietel, Glen Kristiansen, Mark A. Rubin	121
6	ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression 2008 ·BMC Cancer ·Florian Fritzsche, (unknown), Monika Jung, Angelika Tölle, (unknown), Michael Lein, Manfred Johannsen, Manfred Dietel, Klaus Jung, Glen Kristiansen	56
7	Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies 2007 ·British Journal of Urology ·Carsten Stephan, (unknown), Hellmuth‐Alexander Meyer, Glen Kristiansen, Sabine Ziemer, Serdar Değer, Michael Lein, Stefan A. Loening, Klaus Jung	26
8	Treatment of varicocele with reference to age: a retrospective comparison of three minimally invasive procedures 2006 ·Surgical Endoscopy ·(unknown), Matthias May, B. Hoschke, C. Helke, Michael Lein, Jan Roigas, Manfred Johannsen	39
9	Complications, Urinary Continence, and Oncologic Outcome of 1000 Laparoscopic Transperitoneal Radical Prostatectomies—Experience at the Charité Hospital Berlin, Campus Mitte 2006 ·European Urology ·Michael Lein, (unknown), (unknown), (unknown), Jan Roigas, Andreas Wille, Klaus Jung, Glen Kristiansen, Dietmar Schnorr, Stefan A. Loening, Serdar Değer	72
10	Lycopene Effects on Rat Normal Prostate and Prostate Tumor Tissue 2005 ·Journal of Nutrition ·Ulrich Siler, (unknown), Volker Spitzer, Nicole Seifert, (unknown), (unknown), Luca Barella, Willi Hunziker, Michael Lein, Regina Góralczyk, (unknown)	23
11	mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. 2003 ·PubMed ·Ralf Lichtinghagen, Petra B. Musholt, Carsten Stephan, Michael Lein, Glen Kristiansen, Steffen Hauptmann, Birgit Rudolph, Dietmar Schnorr, Stefan A. Loening, Klaus Jung	15
12	Molekulare Formen des PSA in der Diagnostik des Prostatakarzinoms 2003 ·Journal für Kardiologie (Krause & Pachernegg GmbH) ·Michael Lein	1
13	mRNA expression of the five membrane‐type matrix metalloproteinases MT1–MT5 in human prostatic cell lines and their down‐regulation in human malignant prostatic tissue 2003 ·The Prostate ·Monika Jung, (unknown), Gernot Keyszer, Michael Lein, Glen Kristiansen, Dietmar Schnorr, Stefan A. Loening, Klaus Jung	25
14	Vergleichende Einschätzung der diagnostischen Aussagekraft der Kenngrößen freies PSA, Alpha1-Antichymotrypsin-PSA und komplexiertes PSA in der Diagnostik des Prostatakarzinoms 2001 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Ki‐Young Jung, Michael Lein, (unknown), Dietmar Schnorr	1
15	Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma 2000 ·International Journal of Cancer ·Michael Lein, Klaus Jung, (unknown), (unknown), (unknown), Carsten Stephan, Steffen Hauptmann, Birgit Rudolph, Dietmar Schnorr, Stefan A. Loening	54
16	Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model 2000 ·The Prostate ·Michael Lein, Klaus Jung, (unknown), Tayyaba Hasan, Bernhard Ortel, Dietmar Borchert, (unknown), Dietmar Schnorr, (unknown)	25
17	Metalloproteinases and Tissue Inhibitors of Matrix‐Metalloproteinases in Plasma of Patients with Prostate Cancer and in Prostate Cancer Tissue 1999 ·Annals of the New York Academy of Sciences ·Michael Lein, (unknown), Klaus Jung, (unknown), (unknown), Dietmar Schnorr, (unknown)	9
18	Analytical Aspects regarding the Measurement of Metalloproteinases 1999 ·Annals of the New York Academy of Sciences ·Michael Lein, Klaus Jung, (unknown), Dietmar Schnorr, Stefan A. Loening	2
19	The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia 1997 ·Cancer ·Carsten Stephan, Michael Lein, Klaus Jung, Dietmar Schnorr, Stefan A. Loening	83
20	The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia 1997 ·Cancer ·Carsten Stephan, Michael Lein, Klaus Jung, Dietmar Schnorr, Stefan A. Loening	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact